 Metabolic considerations choice therapy patient hypertension objective patients hypertension blood pressure associated morbidity mortality Recent assessments clinical trials risk stroke antihypertensive therapy degree success coronary artery disease CAD many explanations CAD possibility therapy clinical trials diuretics beta-adrenoreceptor blockers patient risk coronary atherosclerosis lethal arrhythmias classes antihypertensive agents initial therapy diuretics beta-adrenoreceptor blockers angiotensin-converting enzyme ACE inhibitors calcium entry blockers metabolic effects thiazide diuretics electrolyte disturbances hypokalemia hypomagnesemia hyponatremia dyslipidemia increased triglycerides abnormalities glucose metabolism hyperglycemia hyperinsulinemia peripheral insulin resistance hyperuricemia beta-Adrenoreceptor blockers many metabolic adverse reactions beta-Adrenoreceptor blockers intrinsic sympathomimetic activity ISA dyslipidemias high-density lipoprotein cholesterol triglycerides abnormalities glucose metabolism hyperglycemia hyperinsulinemia peripheral insulin resistance beta-Adrenoreceptor blockers ISA third-generation beta-blockers selective partial agonist activity celiprolol dilevalol dyslipidemia date abnormalities glucose metabolism ACE inhibitors triglycerides high-density lipoprotein cholesterol captopril insulin sensitivity Calcium entry blockers neutral